RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.